Oncothyreon appoints Diana Hausman as Vice President of Clinical Development

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nSEATTLE, WA, Aug. 4 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY)\n(the "Company") today announced the appointment of Diana Hausman, M.D., as\nVice President, Clinical Development at Oncothyreon. In this position, Dr.\nHausman will be responsible for planning and implementing the clinical\ndevelopment program for the Company's pipeline of oncology product candidates.\n\n\n"Dr. Hausman is an experienced oncologist who brings an extensive\nbackground in drug development to her new role at Oncothyreon," said Robert L.\nKirkman, M.D, President and Chief Executive Officer. "Her leadership and\nknowledge of all aspects of cancer drug development will be very important as\nwe prepare to move both PX-866, our inhibitor of PI-3 kinase, and PX-478, our\ninhibitor of hypoxia inducible factor 1-alpha, into Phase 2 trials. We are\ndelighted to have her join our team."\n\n\n"I am very pleased to join Oncothyreon at this particular time in the\ndevelopment of PX-866 and PX-478," said Dr. Hausman. "It is a unique\nopportunity to contribute to the registration strategy for two promising small\nmolecule product candidates, each directed at an exciting target at the\nforefront of current cancer drug research."\n\n\nDr. Hausman joins Oncothyreon from Zymogenetics, Inc., Seattle,\nWashington, where she held a number of clinical research positions from 2005\nto 2009, most recently as Senior Director of Clinical Research with\nresponsibility for all therapeutic areas, including oncology, autoimmune\ndisease and virology. Prior to Zymogenetics, Dr. Hausman led a global drug\ndevelopment team at Berlex Inc. in Seattle from 2002 until 2005. Dr. Hausman\nwill assume her new role at Oncothyreon on September 1, 2009.\n\n\nAbout Oncothyreon\n\n\nOncothyreon is a biotechnology company specializing in the development of\ninnovative therapeutic products for the treatment of cancer. Oncothyreon's\ngoal is to develop and commercialize novel synthetic vaccines and targeted\nsmall molecules that have the potential to improve the lives and outcomes of\ncancer patients. For more information, visit www.oncothyreon.com.\n\n\nForward Looking Statements\n\n\nIn order to provide Oncothyreon's investors with an understanding of its\ncurrent intentions and future prospects, this release contains statements that\n...

More updates from Cascade Copper Corp.